Entries |
Document | Title | Date |
20100267621 | Antimicrobial Compounds and Formulations - The invention relates to the use of a molecule comprising a backbone of 2 to 35 non-hydrogen atoms in length, having covalently attached thereto at least two bulky and lipophilic groups and having at least one more cationic than anionic moiety, in the manufacture of a medicament for destabilising microbial cell membranes and the use as a membrane acting antimicrobial agent of a molecule comprising a backbone of 2 to 35 non-hydrogen atoms in length, having covalently attached thereto a super bulky and lipophilic group comprising at least 9 non-hydrogen atoms and having at least two more cationic than anionic moieties and to methods of treatment involving such molecules, in particular peptides including peptide derivatives, and peptidomimetics. | 10-21-2010 |
20100267622 | Methods to activate or block the HLA-E/Qa-1 restricted CD8+ T cell regulatory pathway to treat immunological disease - Methods are provided for inhibiting or enhancing down-regulation of an antigen-activated HLA-E+ T cell by an HLA-E-restricted CD8+ T cell comprising contacting the HLA-E* T cell and CD8+ T cell with an agent which inhibits or enhances, respectively, binding between (i) T cell receptor (TCR) on the surface of the CD8+ T cell and (ii) a self peptide presented by HLA-E on the surface of the HLA-E+ T cell, thereby inhibiting or enhancing, respectively, down-regulation of the antigen-activated HLA-E+ T cell. Compositions comprising agents which inhibit or enhance/activate, respectively, binding between (i) T cell receptor (TCR) on the surface of a CD8+ T cell and (ii) a self peptide presented by HLA-E on the surface of a HLA-E+ T cell, and assays for identifying such agents, are provided. | 10-21-2010 |
20100267623 | PEPTIDES WITH CAPACITY TO BIND TO SCURFIN AND APPLICATIONS - The invention relates to peptides of general formula (I), wherein X is absent or X is present and is X | 10-21-2010 |
20100286027 | ANTI-BACTERIAL COMPOSITIONS - The invention relates to an isolated protein for use as an antimicrobial agent comprises a plurality of LRR (leucine rich repeat) domains, each LRR domain independently comprising an amino acid sequence of formula (I): (F1LxxLxL(xxZ) | 11-11-2010 |
20100292135 | INHIBITORS OF RecA ACTIVITIES FOR CONTROL OF ANTIBIOTIC-RESISTANT BACTERIAL PATHOGENS - Compounds for modulating RecA protein activity are provided. In some embodiments, the compounds modulate RecA activity by interfering with assembly of monomeric RecA protein subunits into a nucleoprotein filament. In some embodiments, the compounds modulate RecA activity by interfering with adenosine triphosphate hydrolysis by the RecA protein. Methods of screening for and methods of using the compounds are also provided. | 11-18-2010 |
20100298206 | HYBRID OLIGOMERS, THEIR PREPARATION PROCESS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM - The present invention relates to compositions and methods for producing therapeutic oligomeric compounds. In one aspect the invention relates to methods for administering the oligomeric compounds for the treatment and prevention of disease, for example, a fungal infection, bacterial infection, or cancer, in a mammal. In particular, the invention relates to medicaments comprising various novel oligomeric compounds and pharmaceutically acceptable salts thereof. The compounds of the invention may optionally be administered with at least one of a pharmaceutically acceptable excipient, pharmacologically active agent or a combination thereof. | 11-25-2010 |
20100298207 | PESTICIDAL PROTEINS AND METHODS FOR THEIR USE - Compositions and methods for conferring pesticidal activity to bacteria, plants, plant cells, tissues and seeds are provided. Compositions comprising a coding sequence for a toxin polypeptide are provided. The coding sequences can be used in DNA constructs or expression cassettes for transformation and expression in plants and bacteria. Compositions also comprise transformed bacteria, plants, plant cells, tissues, and seeds. In particular, isolated toxin nucleic acid molecules are provided. Additionally, amino acid sequences corresponding to the polynucleotides are encompassed, and antibodies specifically binding to those amino acid sequences. In particular, the present invention provides for isolated nucleic acid molecules comprising nucleotide sequences encoding the amino acid sequence shown in SEQ ID NO:50-96, or the nucleotide sequence set forth in SEQ ID NO:1-47, as well as variants and fragments thereof. | 11-25-2010 |
20100305025 | RNASE A PEPTIDES, FRAGMENTS AND USES THEREOF - The present invention features isolated polypeptides that have bactericidal and angiogenic activities. The invention features isolated polypeptides comprising amino acid sequences of RNase A ribonucleases, fragments and variants thereof, pharmaceutical compositions, and methods for treatment of a subject. | 12-02-2010 |
20100331240 | METHODS FOR PREVENTION AND TREATMENT OF INFECTIONS WITH SUPRAPHYSIOLOGICAL DOSES OF MANNAN-BINDING LECTIN (MBL) AND FICOLIN-MBL FUSION PROTEINS - The present invention provides methods of treatment and/or prevention of infections, for example, viral and bacterial infections, in individuals, wherein the method comprises administering a supraphysiological amount of mannose-binding lectin (MLB) and/or ficolin-MBL fusion protein to an individual afflicted with an infection or at risk of an infection, such as a bacterial or a viral infection. For example, methods for treatment and/or prevention of Ebola virus infection are provided. | 12-30-2010 |
20110021414 | Chimeric Phage Tail Proteins and Uses Thereof - A multi-protein pyocin-like structure derived from a bacteriophage or a bacteriocin that includes a chimeric tail fiber having a protein receptor binding domain capable of recognizing Lipid A. A multiprotein pyocin-like structure, derived from a bacteriophage or a bacteriocin that includes a chimeric tail fiber capable of recognizing and binding MurNac-L-Ala-D-Glu. A phage including a chimeric tail fiber that binds Lipid A. A plasmid encoding a chimeric ail fiber that binds MurNac-L-Ala-D-Glu. A plasmid encoding a chimeric tail fiber that binds Lipid A. A chimeric bacteriocin or bacteriophage derived tail fiber that includes the amino terminal of the human bactericidal/permeability-increasing protein (BPINTD)—A chimeric bacteriophage or bacteriocin derived tail fiber also includes a binding domain encoding the mammalian Nod2cτD—An antibacterial agent includes a bacteriocidal/permeability-increasing protein receptor domain that binds to Lipid A. An antibacterial agent also includes Nod2 carboxyl-terminus receptor domain that binds MurNac-L-Ala-D-Glu. | 01-27-2011 |
20110028385 | Combination of Immunomodulator and Anti-Pathogenic Agent - A compound comprising combination of an immunomodulator and to at least one anti-pathogenic agent for treating of facultative or strict infections caused by intracellular microorganisms, the components of the combination or association of substances of the invention, the immunomodulator (proteic aggregate of ammonium and magnesium phospholinoleate-palmitoleate anhydride) and at least one substance with antimicrobial properties can be administered either jointly, simultaneously, consecutively or sequentially, in an appropriate form, according to their chemical properties, and in a dose effective against microorganisms in human and animals. | 02-03-2011 |
20110034371 | L. CASEI RHAMNOSUS SECRETED FACTORS AND USE THEREOF - The present invention relates to a composition for inhibiting gastrointestinal inflammation comprising an effective amount of | 02-10-2011 |
20110039761 | TARGETED ANTIMICROBIAL MOIETIES - This invention provides novel targeted antimicrobial compositions. In various embodiments chimeric moieties are provided comprising an antimicrobial peptide attached to a peptide targeting moiety that binds a bacterial strain or species. | 02-17-2011 |
20110039762 | TARGETED ANTIMICROBIAL MOIETIES - This invention provides novel targeted antimicrobial compositions. In various embodiments chimeric moieties are provided comprising an antimicrobial peptide attached to a peptide targeting moiety that binds a bacterial strain or species. | 02-17-2011 |
20110039763 | TARGETED ANTIMICROBIAL MOIETIES - This invention provides novel targeted antimicrobial compositions. In various embodiments chimeric moieties are provided comprising an antimicrobial peptide attached to a peptide targeting moiety that binds a bacterial strain or species. | 02-17-2011 |
20110046039 | POST-EXPOSURE PROPHYLAXIS AND TREATMENT OF INFECTIONS - The invention provides methods and materials for identifying agents for preventing and/or treating anthrax and similar diseases. Embodiments provide strains and model systems for studying non-lethal and lethal exposure to anthrax and similar disease vectors. Embodiments provide materials and methods for using the strains and model systems for differential profiling, such as proteomic profiling, such as differentiation phosphorylation profiling, to target identification and therapeutics discovery and development. Embodiments provide pharmaceutically acceptable compositions, and methods for using them to prevent and/or treat anthrax and similar diseases comprising an agent that decreases the activity of caspase ¼, such as YVAD, and/or an agent that increases the phosphorylation of AKT, such as IB-MECA or Cl-IB-MECA, together with, in particular embodiments, an antibiotic, such as ciprofloxacin. Kits comprising the same are provided as well, among other things. | 02-24-2011 |
20110053834 | NOVEL ANTIBIOTIC PEPTIDE DERIVED FROM RIBOSOMAL PROTEIN L1 OF HELICOBACTER PYLORI AND USE THEREOF - The present invention relates to a new antibiotic peptide and a usage thereof, which are derived from ribosomal protein L1, RPL1 of | 03-03-2011 |
20110053835 | ANTIMICROBIAL PEPTIDES DERIVED FROM CAP18 - The present invention relates to a group of peptidic compounds which have antimicrobial activity. The compounds also have affinity for toxins and especially for bacterial toxins, such as lipopolysaccharide or lipoteichoic acid. The compounds can be used to manufacture medicaments useful for the treatment of bacterial or fungal infections. The medicaments may be administered systemically or locally. | 03-03-2011 |
20110053836 | USE OF DEFENSINS AGAINST TUBERCULOSIS - The present invention relates to a method for killing or inhibiting cells of | 03-03-2011 |
20110065630 | USE OF A OCTREOTIDE AS A THERAPEUTIC AGENT - The present invention is directed to the use of the peptide compound D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-L-threoninol as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical compositions preferably in form of a lyophilisate or liquid buffer solution or artificial mother milk formulation or mother milk substitute containing the peptide D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-L-threoninol optionally together with at least one pharmaceutically acceptable carrier, cryoprotectant, lyoprotectant, excipient and/or diluent. | 03-17-2011 |
20110098214 | LPS OR LIPID A BINDING AGENT AND NOVEL PEPTIDE - A lipopolysaccharide (LPS) and/or lipid A binding agent is provided. The LPS and/or lipid A binding agent contains an LPS and/or lipid A binding peptide, such as a peptide comprising an amino acid sequence of XYSSS (X=K, R, or H), or a derivative thereof, as an active ingredient. The LPS and/or lipid A binding agent is useful as, for example, an LPS and/or lipid A neutralizing agent or an LPS and/or lipid A removing agent. | 04-28-2011 |
20110118174 | TREATMENT SOLUTION AND METHOD FOR PREVENTING POSTERIOR CAPSULAR OPACIFICATION BY SELECTIVELY INDUCING DETACHMENT AND/OR DEATH OF LENS EPITHELIAL CELLS - A treatment solution used to prevent posterior capsular opacification is applied or introduced into the lens capsular bag before, during, or after cataract surgery. The treatment solution may also be applied to an intraocular lens prior to surgery. The treatment solution comprises an ion transport mechanism interference agent, which either alone or in combination with other treatment agents such as an osmotic stress agent and an agent to establish a suitable pH, selectively induces detachment and/or death of lens epithelial cells such that posterior capsular opacification is prevented. While the ion transport mechanism interference agent is capable of interfering with the cellular mechanisms and cell ion distribution of a broad range of cells, a concentration of agent is selected such that the treatment solution interferes selectively with the cellular mechanisms of lens epithelial cells while leaving other ocular cells substantially unharmed. The treatment solution selectively induces cellular death and/or detachment of lens epithelial cells while other ocular cells and tissue remain substantially unharmed and without lengthy preoperative pre-treatment. | 05-19-2011 |
20110136727 | Compositions and methods for rapid selection of pathogen binding agents - Isolated glycan binding peptide complex comprise two or more glycan binding peptides operatively coupled to each other. These are bacterial binding peptide conjugates (e.g., glycan binding peptides) to a multivalent polymer (e.g., a multivalent PEG molecule) or to the surface of particles that create multimeric constructs that inhibit growth and aggregation of microbes. Included is a method of evaluating a substance for the presence of a microbe comprising contacting the substance with a peptide microarray or a peptide complex comprising a plurality glycan binding peptide operatively coupled to a substrate or multivalent linker, wherein the glycan binding peptide is coupled to an array by a linker that is at least 0.5 micrometers in length. | 06-09-2011 |
20110136728 | METHODS OF INCREASING BONE FORMATION USING LEPTIN-RELATED PEPTIDES - The present invention relates to methods of increasing bone formation in patient suffering from a wasting disorder by orally or intranasally administering a pharmaceutically effective amount of a leptin peptide and a pharmaceutically acceptable carrier, wherein the leptin peptide increases serum osteocalcin levels. | 06-09-2011 |
20110143997 | PHAGE RECEPTOR BINDING PROTEINS FOR ANTIBACTERIAL THERAPY AND OTHER NOVEL USES - The subject invention relates in part to novel uses of bacteriophage tail spike proteins (TSPs). Some preferred uses are therapeutic uses in animals, such as chickens, against pathogenic bacteria, such as Salmonella. Fragments of the TSPs can also be used according to the subject invention, particularly protein fragments comprising the phage receptor binding domains (PRBDs), which recognize their hosts and facilitate infection. The binding domains are specific to unique surface structures on bacteria and may be used for a variety of applications according to the subject invention. We have shown that by utilizing these PRBDs, it is possible to exploit the long-established evolutionary relationship between bacteria and their viruses (ie bacteriophages) that specifically infect them. The subject invention also relates in part to novel, synthetic forms of tail spike proteins. In some preferred embodiments, these are hexamers. | 06-16-2011 |
20110143998 | IDENTIFICATION AND USE OF PEPTIDE INHIBITORS OF PROTEIN SYNTHESIS - The present invention discloses compositions of peptide inhibitors of protein synthesis, and methods of identifying peptide inhibitors that are capable of inhibiting protein synthesis through an interaction at a stem-loop H18 in 16S rRNA of a 30S ribosomal subunit. Screening methods for peptides are disclosed, in addition to methods of determining the affinity of a test compound for a ribosomal subunit. | 06-16-2011 |
20110143999 | FOWLICIDINS AND METHODS OF ITS USE - Antimicrobial peptides and methods for their use are provided. The peptides are optimized, truncated versions of chicken cathelicidins (“fowlicidins”). | 06-16-2011 |
20110144000 | ANTIMICROBIAL POLYPEPTIDE - A molecule has a first isolated peptide as shown in SEQ ID NO: 1 or part thereof or a peptide having at least 78% homology to SEQ ID NO:1 conjugated to a second peptide. The second peptide is an amphipatic peptide with an alpha-helical structure or a linear cationic peptide and the first and second peptides have a length of from about 5 to 100 amino acid residues. The molecule is used in medicine as well as for the manufacturing of a medicament for the treatment of a mammal in need thereof, such as for the treatment of a bacterial disease or disorder. | 06-16-2011 |
20110144001 | HIGHLY BRIDGED PEPTIDES FROM ACTINOMADURA NAMIBIENSIS - The invention refers to so-called Labyrinthopeptin derivatives of the formula (I) | 06-16-2011 |
20110152175 | DENDRIMERIC COMPOUNDS COMPRISING AMINO ACIDS, HYPERBRANCHED CORE COMPOUND, PROCESS FOR PREPARATION OF DENDRIMERIC COMPOUNDS COMPRISING AMINO ACIDS AND HYPERBRANCHED CORE COMPOUND, AND USE THEREOF - The invention provides dendrimeric compounds of the formula 1 comprising amino acids, wherein n is an integer of 1-4, T is an alkylidene —(CH2)2CONH(CH2)2- group, R2 is an —NH2 group or a moiety of a primary organic amine, and P is an amino acid and/or peptide moiety, wherein at least one hydrogen atom of at least one amino group is optionally replaced by a protective group, and a hyperbranched core compound of the formula 3, wherein T and R2 are as defined above. The invention provides also a process for the preparation of a dendrimeric compound and a hyperbranched core, wherein the process employs addition reactions of alkyl acrylate and a basic amino acid, and use of a hyperbranched core for the preparation of a dendrimeric compound comprising amino acids. The invention provides also use of dendrimeric compounds for the preparation of the medicament for inhibiting growth of bacterial cells, fungi and tumor cells. | 06-23-2011 |
20110160123 | TARGETING THE EFFLUX SYSTEMS OF MYCOBACTERIUM TUBERCULOSIS - Provided herein are methods of reducing drug resistance in | 06-30-2011 |
20110190198 | PEPTIDE SEQUNCES, THEIR BRANCHED FORM AND USE THEREOF FOR ANTIMICROBIAL APPLICATIONS - The present invention relates to an antibacterial peptide having from the amino to the carboxylic terminal an amino acid sequences selected from the group of: KKIRVRLSA, SEQ ID NO. 1, RRIRVRLSA, SEQ ID NO. 2, KRIRVRLSA, SEQ ID NO. 3, RKIRVRLSA, SEQ ID NO. 4 or a derivative thereof and uses thereof. | 08-04-2011 |
20110230394 | Processes Using Antibiotic Alternatives In Bioethanol Production - Methods for controlling the growth of bacteria in ethanol fermentation systems with antibiotic alternatives, which can be nonoxidizing biocides, stabilized oxidizers, or any combinations thereof, are described. As an option, a process or composition of the present invention can include one or more polycyclic antibacterial peptides. The methods can provide improvements, such as increased ethanol yields with minimal carryover of biocide into co-products of the processes. | 09-22-2011 |
20110245150 | TARGETS FOR TREATMENT OF CHLAMYDIAL INFECTIONS - The present invention relates to a screening method for identification of a compound suitable for the prevention, treatment or/and diagnosis of an infection with Chlamydiaceae. | 10-06-2011 |
20110245151 | Bacteriocins and Novel Bacterial Strains - Novel bacteriocins produced by novel bacterial strains are used for at least reducing the levels of colonization by at least one target bacteria in animals, especially poultry. | 10-06-2011 |
20110251120 | Antimicrobial Peptides and Methods of Identifying the Same - Antimicrobial peptides and methods of identifying the same are provided. | 10-13-2011 |
20110281787 | Pharmaceutical compositions comprising antisense oligonucleotides and methods of using same - The invention provides compositions and associated methods for the antisense treatment of genetic disorders, infections and various other medical conditions. In particular, embodiments of the present invention are directed to pharmaceutical compositions comprising a combination of an antisense oligonucleotide compound conjugated with a positively charged polymer (“ON-PCP”) and a negatively charged polymer. Pharmaceutical compositions in accordance with the present invention have demonstrated improved antisense efficiency and reductions in cell toxicity compared to compositions that contain an oligonucleotide compound conjugated with a positively charged polymer. | 11-17-2011 |
20110288007 | BIOCIDAL FUSION PEPTIDE COMPRISING LL-37 - The present invention relates to a biocidal fusion peptide comprising: a) a peptide LL-37 or an active fragment or active derivative thereof; b) and a further heterologous bioactive peptide or an active fragment thereof, wherein part or all of the amino acid sequence of the fusion peptide is predicted to form an alpha-helix structure for disruption of a pathogen membrane, compositions such as pharmaceutical compositions comprising the same, methods of preparing the peptide and use of the peptides in treatment, in particular for the treatment of bacterial infection and/or fungal infection and/or viral infection. | 11-24-2011 |
20110312875 | PEPTIDIC COMPOUNDS - The present invention provides a compound of formula I, II, III and IV as defined herein and pharmaceutically acceptable derivatives thereof. The present invention further provides use of the compounds of the present invention in the treatment of bacterial infection and in the treatment of HIV infection. Also provided are pharmaceutical compositions comprising the compounds of the present invention. | 12-22-2011 |
20120004160 | METHODS FOR IDENTIFYING AND COMPOUNDS USEFUL FOR THE DIAGNOSIS AND TREATMENT OF DISEASES INVOLVING INFLAMMATION - The present invention relates to agents, and methods for identifying compounds, which agents and compounds result in the inhibition of the activation of macrophages. In addition, the invention relates to compositions and methods for the use thereof in treating conditions that are characterized by activation of macrophages including infections, allograft reactions, inflammation, allergic and autoimmune diseases, metabolic disease, cardiovascular disease, tissue injury, and cancer. | 01-05-2012 |
20120010127 | Compositions Comprising Multiple Bioactive Agents, and Methods of Using the Same - In part, the present invention is directed to compositions comprising a FabI inhibitor and at least one other bioactive agent. In another part, the present invention is directed to antibacterial compositions comprising a compound of formulas I-III and at least one other antibacterial agent. | 01-12-2012 |
20120015870 | PEPTIDES AND COMPOSITIONS FOR PREVENTION OF CELL ADHESION AND METHODS OF USING SAME - Compositions comprising an isolated peptide, which may for example optionally comprise a sequence selected from the group consisting of FDYDWY (SEQ ID NO: 2), SFSQNKSVHSFDYDWYNVSDQADLKN (SEQ ID NO: 3) or CSFSQNKSVHSFDYDWYNVSDQADLKNC (SEQ ID NO: 1), or any cyclized version thereof, and methods of using same, including for treatment of or prevention of formation of microbial biofilms and against adhesion of a cell to a surface. | 01-19-2012 |
20120015871 | COMPLEMENT RECEPTOR 2 TARGETED COMPLEMENT MODULATORS - Modulation of the complement system represents a therapeutic modality for numerous pathologic conditions associated with complement activation. In a strategy to prepare complement inhibitors that are targeted to sites of complement activation and disease, compositions comprising a complement inhibitor linked to complement receptor (CR) 2 are disclosed. The disclosed are compositions can be used in methods of treating pathogenic diseases and inflammatory conditions by modulating the complement system. | 01-19-2012 |
20120015872 | COMPLEMENT RECEPTOR 2 TARGETED COMPLEMENT MODULATORS - Modulation of the complement system represents a therapeutic modality for numerous pathologic conditions associated with complement activation. In a strategy to prepare complement inhibitors that are targeted to sites of complement activation and disease, compositions comprising a complement inhibitor linked to complement receptor (CR) 2 are disclosed. The disclosed are compositions can be used in methods of treating pathogenic diseases and inflammatory conditions by modulating the complement system. | 01-19-2012 |
20120021975 | ANTIBIOTIC PEPTIDES - The invention relates to a peptide or peptide derivative having the general formula: Sub | 01-26-2012 |
20120028883 | COMPLEX AND PRODUCTION PROCESS - A method for preparing a biologically active complex, said method comprising a recombinant protein having the sequence of α-lactalbumin, such as human α-lactalbumin or a fragment thereof but which lacks intra-molecular disulfide bonds, and oleic acid, and process for preparing this are described and claimed. The recombinant protein suitably has cysteines found in the native protein changed to other amino acids, such as alanine. Improvements in recombinant expression, process rationalisation and yields of biologically active complexes, as well as the complexes obtained are also described and claimed. | 02-02-2012 |
20120040887 | COMPOSITION FOR THE TREATMENT OF OSTEOMYELITIS, METHOD FOR PREPARING THE SAME, AND METHOD FOR THE TREATMENT OF OSTEOMYELITIS - The disclosure provides a composition for the treatment of osteomyelitis and a method for preparing the same. The composition includes: 100 parts by weight of water; 0.06-0.1 parts by weight of an antibiotic; and 5-40 parts by weight of a biodegradable thermosensitive polymer, wherein the biodegradable thermosensitive polymer has a structure as following: | 02-16-2012 |
20120071397 | Methods for Hematopoietic Stem Cell Transplantation - The present invention provides methods for treating a subject undergoing hematopoietic stem cell transplantation, methods for increasing a subject's resistance to bacterial or viral infection during and/or following hematopoietic stem cell transplantation, and methods for treating norovirus infection. | 03-22-2012 |
20120077736 | INHIBITOR AGAINST FORMING BIOFILM COMPRISING K-CASEIN MACROPEPTIDE - An inhibitor against the formation of biofilm includes κ-casein macropeptide. The inhibitor prevents or reduces the formation of a biofilm by inhibiting attachment or attachment/invasion followed by biofilm formation on the abiotic or biotic surfaces by | 03-29-2012 |
20120122766 | Novel Polypeptide Having Angiogenesis-Inducing Activity And Antibacterial Activity, And Use Thereof For Medical Purposes - Novel polypeptides which have an excellent angiogenesis-inducing activity and an excellent antibacterial activity and medical uses thereof are disclosed. The amino acid sequences of the novel polypeptides are shown in any one of SEQ ID NOs:1 to 6. These polypeptides have angiogenesis-inducing and antibacterial activities. Such polypeptides are useful for the prevention, amelioration or treatment of skin wounds caused by a cut wound, surgical wound, erosion, burn, decubitus, intractable wound, skin ulcer, leg ulcer, diabetic ulcer, occlusive arterial disease or arteriosclerosis obliteran, and for the prevention, amelioration or treatment of bacterial infection in such skin wounds, and the like. | 05-17-2012 |
20120129762 | MOTILIN-LIKE PEPTIDE COMPOUND HAVING TRANSMUCOSAL ABSORBABILITY IMPARTED THERETO - The present invention aims at providing motilin-like peptide compounds that maintain the gastrointestinal motility stimulating activity of native motilin and which are adapted to have higher absorbability upon transmucosal administration. | 05-24-2012 |
20120165246 | Method of Diagnosis of Infection by Mycobacteria and Reagents Therefor - The present invention provides a method of specifically detecting the presence of one or more Mycobacteria of the | 06-28-2012 |
20120172287 | Polypeptide Having Antibacterial Activity and Angiogenesis-Inducing Activity and Wound-Healing Drug Containing Said Polypeptide - A novel polypeptide which has an excellent angiogenesis-inducing activity and an excellent antibacterial activity, and a novel angiogenesis-inducing agent which contains the polypeptide as an effective ingredient or a novel agent for treating a wound(s) which contains the polypeptide as an effective ingredient are disclosed. The polypeptide of the present invention is a polypeptide whose amino acid sequence is shown in any one of SEQ ID NOs:1 to 6, 8 and 10. The angiogenesis-inducing agent which contains the polypeptide of the present invention as an effective ingredient is useful for the prevention, amelioration or treatment of a disease such as a burns, decubitus, wound, skin ulcer, leg ulcer, diabetic ulcer, occlusive arterial disease and arteriosclerosis obliteran. | 07-05-2012 |
20120184482 | Novel Ubiquitin-Isopeptide Probes - The invention relates to a ubiquitin-isopeptide probe (hereinafter also referred to as UIPP), a method for its preparation, and its use. The invention also provides a method for isolating a deubiquitinating enzyme and a method for activity-based protein profiling (ABPP). | 07-19-2012 |
20120202734 | ANTIBIOTIC, ITS NUCLEOTIDE SEQUENCE, METHODS OF CONSTRUCTION AND USES THEREOF - The present invention belongs to field of biology and medicine, and especially relates to a novel antibiotic, its nucleotide sequence, methods of construction and uses thereof. A novel antibiotic, wherein the end of any peptide of the allosteric colicin is connected linearly to the end of peptide of the | 08-09-2012 |
20120202735 | ANTIMICROBIAL CATIONIC PEPTIDES AND FORMULATIONS THEREOF - Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device. | 08-09-2012 |
20120238491 | IMMUNOLOGICALLY ACTIVE LIPOPEPTIDES AND METHODS FOR USE THEREOF - The present invention relates to the isolation and structure elucidation of 1-peptidyl-2-arachidonoyl-3-stearoyl glyceride (pDAG) as an active chemical entity in the caprine serum fraction, and the discovery of the innate immune modulating activity of pDAG as an endogenous damage associated molecular pattern | 09-20-2012 |
20120252720 | COMPOSITIONS FOR TREATMENT OF EAR DISORDERS AND METHODS OF USE THEREOF - The present invention relates to compositions and methods useful for the treatment of ear disorders, administered to a treated ear in the form of a foam or a mousse. Administering a medicament in such forms will increase the residence time of the medicament in the ear canal, provide relatively uniform distribution of the composition, and can increase the penetration of the active pharmaceutical ingredient in the affected area, may release active substances slowly, enhance treatment effectiveness, increase compliance and is more convenient to use than currently available ear medications. The administration in the form of a foam or a mousse may preferably be provided as a metered dose, of a volume suitable to fill the ear canal. | 10-04-2012 |
20120264678 | METHODS OF USING [3.2.0] HETEROCYCLIC COMPOUNDS AND ANALOGS THEREOF FOR TREATING INFECTIOUS DISEASES - Disclosed are methods of treating infectious diseases comprising administering to an animal, a therapeutically effective amount of a heterocyclic compound. The animal is a mammal, preferably a human or a rodent. | 10-18-2012 |
20120283173 | NOVEL COMPOSITIONS FOR TREATING PSEUDOMONAS INFECTION - The invention relates to a HNK-I mimetic peptide or a polypeptide comprising such HNK-I mimetic peptide for treating or preventing a | 11-08-2012 |
20120283174 | ANTIBIOFILM GLYCOPEPTIDES - The present invention relates to peptides and compositions that have antibiofilm properties. In particular, the peptides and compositions of the invention can be used for the treatment or prevention of various conditions including dental caries, gingivitis, periodontitis, oral mucositis, dry mouth and xerostomia. | 11-08-2012 |
20120289455 | Monocarbams - The invention relates to compounds of formula (I): | 11-15-2012 |
20120295837 | NOVEL ANTIMICROBIAL AGENTS - A novel class of antimicrobial polymeric agents, which include a plurality of amino acid residues, such as positively charged amino acid residues, and at least one hydrophobic residue linking therebetween, such as an omega-amino-fatty acid residue, designed to exert antimicrobial activity while being stable, non-toxic and avoiding development of resistance thereto and a process of preparing same are disclosed. Further disclosed are pharmaceutical compositions containing same and a method of treating medical conditions associated with pathological microorganisms, a medical device, an imaging probe and a food preservative utilizing same. Further disclosed are conjugates of an amino acid residue and a hydrophobic moiety residue and a process of preparing same. | 11-22-2012 |
20120295838 | Selective poly-substituted glycine antibiotics and related compositions - Antimicrobial peptoid compounds and related compositions as can be used against bacteria effectively and selectively. | 11-22-2012 |
20130012428 | LIQUID ANTIMICROBIAL COMPOSITIONS - The present invention relates to liquid antimicrobial compositions having a high anti-microbial activity. The invention further relates to a method for preparing the liquid antimicrobial compositions as well as their use as a preservative in food products. | 01-10-2013 |
20130029902 | CXC CHEMOKINE RECEPTOR 4 (CXCR4) ANTAGONISTIC POLYPEPTIDE - A peptide having the following amino acid sequence: | 01-31-2013 |
20130059773 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATION AND NEUTROPENIA - The present invention concerns compounds modulating apoptosis of neutrophil cells. In particular, the invention concerns compounds inhibiting an interaction between Proliferating Cell Nuclear Antigen (PCNA) and proteins binding to cytoplasmic PCNA in neutrophil cells, for use in the treatment of a disease involving a neutrophil-dependent inflammatory process. The invention also relates to a method for the identification of a compound for use in the treatment of a neutrophil-dependent inflammatory process. The invention further relates to peptides for use in the treatment of neutropenia. | 03-07-2013 |
20130096051 | LECTINS AND USES THEREOF - The present invention relates to chemical compounds, methods for their discovery, and their therapeutic and re-search use. In particular, the present invention provides antiviral and antimicrobial lectin compounds (BanLec) isolated from bananas. These compounds have low mitogenicity and pro-inflammatory activity whilst maintaining anti-HIV-1 activity. | 04-18-2013 |
20130130969 | ANTIMICROBIAL PEPTIDE, BRANCHED FORMS THEREOF AND THEIR USE IN THE TREATMENT OF BACTERIA INFECTIONS - The instant invention refers to an antibacterial peptide with all aminoacids in D-configuration, possessing strong antimicrobial activity against Gram-negative and Gram-positive bacteria and | 05-23-2013 |
20130150285 | THERAPEUTIC AND COSMETIC USES AND APPLICATIONS OF CALRETICULIN - Therapeutic and cosmetic uses and applications of calreticulin are provided. In particular, the invention relates to therapeutic and cosmetic uses and applications of calreticulin to a patient in need of such treatment including in tissue repair, wound healing, ulcers, reducing scar formation, and reducing or eliminating wrinkles. | 06-13-2013 |
20130157931 | MITOCHONDRIAL PENETRATING PEPTIDES AS CARRIERS FOR ANTIMICROBIALS - There is described herein compounds comprising a mitochondrial penetrating peptide (MPP) conjugated to an antimicrobial, and their method of use. | 06-20-2013 |
20130203652 | DIFFOCINS AND METHODS OF USE THEREOF - This disclosure relates to the discovery and isolation of the entire cluster of genes encoding R-type high molecular weight bacteriocins that specifically kill | 08-08-2013 |
20130203653 | BACTERIAL-DERIVED BLIS FOR TREATMENT OF ACNE - This invention relates to a treatment of acne. Specifically, the invention is directed to the use of bacteriocin-like inhibitory substances (BLIS), isolated from | 08-08-2013 |
20130210707 | PEPTIDE HAVING ANTIMICROBIAL OR ANTI-INFLAMMATORY ACTIVITY AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS AN ACTIVE INGREDIENT - The present invention relates to a peptide having antibacterial or anti-inflammatory activity and a pharmaceutical composition containing the same as an active ingredient, and more particularly to a peptide having antibacterial or anti-inflammatory activity against dental bacteria, including periodontal pathogens, and bacteria causing atopic dermatitis, and to a pharmaceutical composition containing the peptide as an active ingredient. The inventive peptide having antibacterial or anti-inflammatory activity can be used for the treatment of both dental infectious diseases, including periodontitis or peri-implantitis, and inflammations, including atopy, psoriasis or arthritis. | 08-15-2013 |
20130231275 | AMINIOTHIAZOLES AND THEIR USES - The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of diseases particularly bacterial infections. | 09-05-2013 |
20130244928 | ANTIMICROBIAL PEPTIDES AND DERIVED METAPEPTIDES - The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence. | 09-19-2013 |
20130252880 | Dendrimeric Peptides, Pharmaceutical Compositions And Methods Of Using The same - Novel dendrimeric peptide compounds are disclosed that have a formula represented by the following formula I: | 09-26-2013 |
20130267457 | PEPTIDE INHIBITORS OF PROTEIN SYNTHESIS - The present invention discloses compositions of peptide inhibitors of protein synthesis, and methods of identifying peptide inhibitors that are capable of inhibiting protein synthesis through an interaction at a stem-loop H18 in 16S rRNA of a 30S ribosomal subunit. Screening methods for peptides are disclosed, in addition to methods of determining the affinity of a test compound for a ribosomal subunit. | 10-10-2013 |
20130274173 | STABLE HELICAL IONIC POLYPEPTIDES - The invention provides polymers comprising Formula I: | 10-17-2013 |
20130296227 | ANTIMICROBIAL CATIONIC PEPTIDES AND FORMULATIONS THEREOF - Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device. | 11-07-2013 |
20130338058 | USE OF LIPID CONJUGATES IN THE TREATMENT OF CONJUNCTIVITIS - In one embodiment, the invention provides a method of suppressing, inhibiting, preventing, or treating conjunctivitis in a subject, comprising the step of administering an effective amount of a lipid or phospholipid moiety bound via an ester or amide bond to a physiologically acceptable monomer, dimer, oligomer, or polymer, and/or a pharmaceutically acceptable salt or a pharmaceutical product thereof to a subject with conjunctivitis. | 12-19-2013 |
20130345119 | MULTIMERIC ANTIMICROBIAL PEPTIDE COMPLEX WHICH IS DISPLAYED ON CELL SURFACE - The present invention provides an antimicrobial peptide polymer comprising at least one monomer which is digested by pepsin, a multimeric antimicrobial peptide complex comprising the polymer and a cell surface anchoring motif linked to the polymer, an antimicrobial microorganism displaying the multimeric antimicrobial peptide complex, an antimicrobial composition comprising the same, a method of treating an infectious disease caused by bacteria, yeast or fungi by administering the antimicrobial composition, and a method for producing the antimicrobial microorganism. According to the invention, living microorganisms displaying an antimicrobial peptide on the cell surface thereof may be administered in vivo without having to lyse the microbial cell and isolate and purify the antimicrobial peptide, so that the antimicrobial peptide exhibits antimicrobial activity. Thus, the antimicrobial peptide may be produced at significantly reduced costs so that it may have widespread use. | 12-26-2013 |
20140018287 | BRIDGE-HELIX CAP: TARGET AND METHOD FOR INHIBITION OF BACTERIAL RNA POLYMERASE - It has been discovered that the Sal target represents a new and promising target for antibacterial drug discovery. The Sal target is distinct from the rifamycin target and from the CBR703 target. This indicates that antibacterial compounds that function through the Sal target should exhibit no, or minimal, cross-resistance with rifamycins and CBR703. This further implies that it should be possible to co-administer antibacterial compounds that function through the Sal target together with a rifamycin, together with CBR703, or together with both a rifamycin and CBR703, in order to achieve additive or synergistic antibacterial effects and in order to suppress or eliminate the emergence of resistance. | 01-16-2014 |
20140024576 | HEPTOSE DERIVATIVES FOR USE IN THE TREATMENT OF BACTERIAL INFECTIONS - Compounds having the general formula (I) pharmaceutical compositions containing them for use in inhibiting bacterial heptose biosynthesis and thereby lowering or suppressing bacterial virulence. | 01-23-2014 |
20140038882 | Stable Pexiganan Formulation - The invention provides chemically and physically stable topical formulations of pexiganan, and methods of preparing the same. | 02-06-2014 |
20140066363 | CARBOHYDRATE NANOPARTICLES FOR PROLONGED EFFICACY OF ANTIMICROBIAL PEPTIDE - A nanoparticle includes a carbohydrate carrier and a bacteriocin. A method for prolonging efficacy of a bacteriocin against a food pathogen includes providing the bacteriocin in a delivery system, and inhibiting the food pathogen by the bacteriocin. A duration of efficacy of the bacteriocin against the food pathogen when the bacteriocin is provided in the delivery system exceeds a duration of efficacy of the bacteriocin when the bacteriocin is provided without the delivery system. | 03-06-2014 |
20140094401 | MITRECIN A POLYPEPTIDE WITH ANTIMICROBIAL ACTIVITY - The present invention provides a Mitrecin A polypeptide useful in prevention and treatment of one or more bacteria. Also provided is a method to kill or prevent growth of one or more bacteria comprising contacting the one or more bacteria with a Mitrecin A polypeptide. The target bacteria can be selected from the group consisting of a Gram-positive bacterium, a Gram-negative bacterium, or both. In one embodiment, the present invention is drawn to a polynucleotide encoding a Mitrecin A polypeptide, a vector comprising the polynucleotide, a host cell comprising the polynucleotide, or a composition comprising the Mitrecin A polypeptide, the polynucleotide, the vector, or the host cell. | 04-03-2014 |
20140128312 | Antimicrobial lytic peptides - This invention relates to novel lytic peptides which are effective in treating citrus plant diseases including canker and greening. The invention also relates to antimicrobial compositions comprising lytic peptides and the use of such compositions in methods for treating diseases of citrus plants. | 05-08-2014 |
20140128313 | ANTIMICROBIAL PEPTIDES AND USES THEREFORE - Materials and methods for making and using cationic anti-microbial peptides (CAMPs), and compositions containing such peptides. | 05-08-2014 |
20140148378 | ANTIBACTERIAL PEPTIDES - The present invention relates to antibacterial peptides and analogs thereof, e.g., originating from, derived from, isolated and/or purified from mammalian milk, that reduce, inhibit and/or prevent the growth or proliferation of a bacterial organism. | 05-29-2014 |
20140148379 | Control of Unwanted Bacteria in Fermentation Systems with Bacteriocin - A method of controlling unwanted bacteria in fermentation processes comprising contacting reactants of the process with an effective amount of bacteriocin. Bacteriocin, both indigenous and produced from independent sources, and optionally bacteriocin plus bacteriophages virulent for unwanted bacteria are used to reduce and control unwanted bacteria. | 05-29-2014 |
20140148380 | MOLECULAR ROADBLOCKS FOR RpoN BINDING SITES - The present invention relates to, inter alia, a method for repressing transcription and/or gene expression from RpoN binding sites (or promoters) or cryptic promoters upstream of RpoN binding sites. The method comprises providing an agent that specifically and selectively binds to RpoN promoter sequences to inhibit or repress the expression of genes downstream of that promoter; and contacting the RpoN promoter with the agent. Agents for repressing transcription and/or gene expression from RpoN promoters are also provided. The agent can be a composition that binds specifically to the −24, −12, or −24/−12 site(s) for RpoN promoter interference. Synthetic peptides, vectors, and host cells are also provided. | 05-29-2014 |
20140155318 | PEPTIDES AND COMPOSITIONS FOR PREVENTION OF CELL ADHESION AND METHODS OF USING SAME - Compositions comprising an isolated peptide, which may for example optionally comprise a sequence selected from the group consisting of FDYDWY (SEQ ID NO: 2), SFSQNKSVHSFDYDWYNVSDQADLKN (SEQ ID NO: 3) or CSFSQNKSVHSFDYDWYNVSDQADLKNC (SEQ ID NO: 1), or any cyclized version thereof, and methods of using same, including for treatment of or prevention of formation of microbial biofilms and against adhesion of a cell to a surface. | 06-05-2014 |
20140194344 | FUSION PEPTIDE DESIGNED TO REDUCE PLAQUE BACTERIA AND YEAST IN THE ORAL CAVITY - The present invention relates generally to dental diseases, caries and periodontal disease. More specifically, the invention relates to Lactoferrin and PAK fusion peptides (PAK-LF), along with therapeutic, diagnostic and research uses for these polypeptides. The present invention also provides methods of treating dental diseases, caries and periodontal disease. | 07-10-2014 |
20140221273 | Anti-Microbial Peptides and Methods of Use Thereof - The present disclosure provides antimicrobial peptides, and compositions comprising same. The present disclosure further provides methods of inhibiting microbial growth. | 08-07-2014 |
20140243255 | TREATMENTS FOR MYCOBACTERIUM TUBERCULOSIS - The technology described herein relates to treatments for tuberculosis which target the ClpP1P2 protease complex, including ClpC1. Further embodiments relate to assays and screens for modulators of the ClpP1P2 protease complex, including ClpC1. | 08-28-2014 |
20140256614 | COMPOSITIONS AND METHODS FOR AUGMENTING PERMEABILITY BARRIERS - Compositions and methods for activating MK2, augmenting permeability barriers, such as epithelial and/or endothelial barriers, and treating diseases, conditions, disorders, and/or injuries associated therewith, such as pulmonary edema and other lung diseases and injuries are provided herein. | 09-11-2014 |
20140274876 | CARIES RISK TEST FOR PREDICTING AND ASSESSING THE RISK OF DISEASE - Provided are methods, test devices, and diagnostic kits for predicting, assessing, and diagnosing the risk of a disease using salivary analysis. The methods comprise providing a whole (unfractionated) saliva sample from a subject; contacting an aliquot of the saliva with two or more lectins under conditions that allow the two or more lectins to bind to a lectin-binding component of the saliva; detecting the amount of bound lectin; and comparing the amount of bound lectin to the amount known to bind a saliva sample from a control patient, to predict the risk of a disease in the subject. Also provided are methods for reducing the risk of a disease and a method for assessing the risk of the disease at a defined level. | 09-18-2014 |
20140274877 | HYDROCHLORIDE SALTS OF AN ANTIBIOTIC COMPOUND - The present invention relates to a compound of formula I: | 09-18-2014 |
20140274878 | AMINOTHIAZOLES AND THEIR USES - The present application describes organic compounds of Formula (I) | 09-18-2014 |
20140287988 | MACROGOL 15 HYDROXYSTEARATE FORMULATIONS - Provided herein are compositions, which include an active pharmaceutical ingredient and macrogol 15 hydroxystearate, and methods for using the same for treating diseases or disorder. | 09-25-2014 |
20140287989 | Compounds Binding to the Bacterial Beta Ring - The present invention relates to compounds which bind to the hydrophobic pocket of the β clamp, i.e., to the surface of the β ring with which said protein interacts with other proteins of the bacterial replication complex during DNA replication. These compounds are derived from the acetylated peptide AcQLDLF (P6) to improve their affinity to their target. | 09-25-2014 |
20140296132 | Anti-bacterial Polypeptides and Pathogen Specific Synthetic Antibodies - The present invention provides polypeptides, compositions thereof, and methods for use of the polypeptides in treating bacterial infection and for use as disinfectants. | 10-02-2014 |
20140303070 | PROCESS FOR THE MANUFACTURE OF AJOENE DERIVATIVES - The present invention relates to the compound (E,Z)-ajoene of formula (1) for use in treatment of bacterial infections. Another aspect of the present invention is a composition comprising (E,Z)-ajoene of formula (1) and at least one antibiotic. Yet another aspect of the invention relates to a method for manufacturing (E,Z) ajoene of formula (1) wherein the conformation of the internal C═C— bond can be either E or Z or a mixture thereof, said method comprising reacting allicin of formula (3) with an acid in the presence of a solvent to provide (E,Z ajoene) of formula (1) as defined above. Yet another aspect of the invention is (E,Z)-ajoene of formula 1 obtainable by the method described above. | 10-09-2014 |
20140309161 | Modified antibiotic peptides having variable systemic release - The invention relates to modified antibiotic peptides, in particular derivatives of apidaecin and oncocin, preferably having increased stability, reduced immunoreaction, and improved pharmacokinetics. In the invention, the peptide antibiotics are reversibly protected by means of a linker having the polymer polyethylene glycol (PEG). The peptide linker contains a recognition sequence for trypsin-like serum proteases. In the apidaecin derivatives, the linker and the PEG are bonded to a side chain. In the serum, the linker is cut by serum proteases and PEG is separated off. The released peptide still contains remnants of the linker, which are still bonded to the amino group in the side chain. Astonishingly, said remaining remnants of the linker impair the activity of the antimicrobial peptide only a little or not at all. | 10-16-2014 |
20140309162 | NOVEL ANTIBACTERIAL AND FUNGICIDAL PEPTIDE IN WHICH LYSINE AND TRYPTOPHAN RESIDUES ARE REPEATED, AND USE THEREOF - The present invention relates to an antibacterial and fungicidal peptide in which a lysine and tryptophan dipeptide is repeated. More specifically, the antibacterial and fungicidal peptide of the present invention, in which lysine and tryptophan dipeptide is repeated four times, shows excellent antibacterial activities with respect to gram-positive bacteria, gram-negative bacteria and antibiotic-resistant strains by affecting the inner membrane of harmful microorganisms, has remarkable fungicidal activities with respect to pathogenic fungi and antibiotic-resistant fungi, and shows little cytotoxicity, and thus can be useful for a pharmaceutical composition, a cosmetic composition, agricultural chemicals, a food preservative, a cosmetic preservative, and a pharmaceutical preservative. | 10-16-2014 |
20150045284 | CRYSTAL STRUCTURE OF A TYPE IB P-TYPE ATPase - The present invention relates to crystals of a type IB P-type ATPase having the space group P1 and methods for purification and growing said crystals. The invention also presents methods for identifying an inhibitor of a type IB P-type ATPase for example by determining binding interactions between an inhibitor and a set of binding interaction sites in said type IB P-type ATPase. | 02-12-2015 |
20150045285 | BIOFILM INHIBITOR - The biofilm inhibitor of the present invention contains a lectin, at least one recognizable sugar chain of which is N-acetylglucosamine (G/LcNAc). | 02-12-2015 |
20150057217 | SHORT DESIGNED PEPTIDES POSSESSING SELECTIVE ACTIONS AGAINST BACTERIA AND CANCER CELLS - The present invention relates to amphiphilic peptides having antibacterial and/or antitumor activity, and to therapeutic and non-therapeutic compositions comprising these peptides. The peptides are of structural formula I or II shown below | 02-26-2015 |
20150072920 | ANTIMICROBIAL COMPOSITIONS AND USES THEREOF - The present invention relates to an antimicrobial composition having activity against Gram-positive and Gram-negative bacteria. The composition is a) a composition comprising at least two organic acids selected from the group consisting of lactic acid, acetic acid, benzoic acid and citric acid; b) a composition comprising at least two bacteriocin selected from the group consisting of pediocin, Nisin and reuterin; c) a composition comprising pediocin and at least two organic acids selected from the group consisting of lactic acid, acetic acid, benzoic acid and citric acid; or d) a composition comprising reuterin and at least one organic acid selected from the group consisting of lactic acid, acetic acid, benzoic acid and citric acid. The present invention also relates to the use of said compositions for sanitizing and/or disinfecting surfaces and method thereof. | 03-12-2015 |
20150072921 | METHOD FOR THE APPLICATION OF A SUBSTANCE TO ELIMINATE AN INFECTIOUS AGENT LIVING WITHIN AN INSECT VECTOR AS A MEANS OF CONTROL OF THE SPREAD OR ELIMINATION OF DISEASE - A method of reducing the spread of disease by inhibiting the growth of or eliminating harmful bacteria which are the cause of the disease in an organism or damage to organic material. The method inhibits bacterial growth in the organism without harming the organism or other organisms in the environment. The method includes formulating an antimicrobial agent that is taken up to the vector organism known to spread disease due to the presence of harmful microbes such as bacteria living in the organism. The antimicrobial agent eradicates and/or inhibits the future growth of the bacteria in the organism, thereby leaving the organism free of the infecting bacteria while not being a poison to the organism. | 03-12-2015 |
20150087579 | ANTIMICROBIAL PEPTIDES - A novel antimicrobial peptide includes at least eight successive amino acids, the peptide exhibiting a sequence having the following formula: Ter | 03-26-2015 |
20150087580 | ANTIMICROBIAL CATIONIC PEPTIDES AND FORMULATIONS THEREOF - Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device. | 03-26-2015 |
20150087581 | Immunosuppression Modulating Compounds - The present invention provides immunosuppression compounds to inhibit the programmed cell death 1 (PD1) signalling pathway. The present invention further provides peptide based compositions for treatment of cancer or treatment of infections via immunopotentiation caused by inhibition of immunosuppressive signaling induced by PD-1, PD-L1, or PD-L2 and therapies using them, immunopotentiative substrates included as the active ingredient. Further, the invention provides an application of the compositions containing the peptide moieties for preventive and/or therapeutic agents for cancer, cancer metastasis, immunodeficiency, an infectious disease or the like and an application of peptide moieties as a testing or diagnostic agent or a research agent for such a disease. | 03-26-2015 |
20150126433 | GROWTH FACTORS FOR THE TREATMENT OF MYCOBACTERIAL INFECTION - Described herein are novel methods and kits for treating mycobacterium infections with KGF. The methods include administering an amount of KGF effective to treat the mycobacterium infection. The mycobacterium may be | 05-07-2015 |
20150126434 | ANTIMICROBIAL PEPTIDE AND USE THEREOF - A composition including an artificially synthesized antimicrobial peptide that is not present as a mature peptide in nature. The composition includes an artificially synthesized peptide that has an antimicrobial activity against at least one strain of bacteria or fungi and includes an amino acid sequence represented by any one of SEQ ID NOs: 1 to 6 or an amino acid sequence formed by substituting, deleting and/or adding one, two or three amino acid residues in/from/to the amino acid sequence, and further including at least one species of pharmaceutically acceptable carrier. | 05-07-2015 |
20150133365 | Polypeptide Having Antibacterial Activity and Angiogenesis-Inducing Activity and Wound-Healing Drug Containing Said Polypeptide - A novel polypeptide which has an excellent angiogenesis-inducing activity and an excellent antibacterial activity, and a novel angiogenesis-inducing agent which contains the polypeptide as an effective ingredient or a novel agent for treating a wound(s) which contains the polypeptide as an effective ingredient are disclosed. The polypeptide of the present invention is a polypeptide whose amino acid sequence is shown in any one of SEQ ID NOs:1 to 6, 8 and 10. The angiogenesis-inducing agent which contains the polypeptide of the present invention as an effective ingredient is useful for the prevention, amelioration or treatment of a disease such as a burns, decubitus, wound, skin ulcer, leg ulcer, diabetic ulcer, occlusive arterial disease and arteriosclerosis obliteran. | 05-14-2015 |
20150313836 | Dry Pharmaceutical Compositions for Topical Delivery of Oral Medications, Nasal Delivery and to Treat Ear Disorders - In one aspect, a dry formulation for the effective administration of multiple medications simultaneously for one or more ailments may be provided. The dry formulations include one or more of the following actives in combination with pharmaceutically acceptable excipients or additives: a) at least one antibiotic; b) at least one anti-inflammatory steroid; and c) at least one antifungal agent. | 11-05-2015 |
20150315241 | Antibiotic Peptides - This invention concerns novel antibiotic peptide and peptide derivates, especially for use in medicine. Further, the invention relates to compositions and methods for killing microbes, like bacteria or fungus, and methods to treat microbial infections. The invention further relates to a method for drug screening analysis. The peptides and peptide derivates have the general formula Sub | 11-05-2015 |
20150335030 | LIQUID NISIN COMPOSITIONS - The present invention relates to liquid nisin compositions having a high anti-microbial activity. The invention further relates to a method for preparing the liquid nisin compositions as well as their use as a preservative in food products. | 11-26-2015 |
20150336957 | NITROGEN CONTAINING HETEROCYCLIC COMPOUNDS - Compounds of Formula (I), their preparation and use in preventing or treating bacterial infections are disclosed. | 11-26-2015 |
20150374673 | Combination Therapy for the Treatment of Nosocomial Pneumonia - The present invention relates to a method of treatment of nosocomial pneumonia using a combination of ceftazidime (a third generation cephalosporin) and avibactam (a novel β-lactamase inhibitor), optionally with one or more additional therapeutic agents. | 12-31-2015 |
20150374786 | COMPOSITIONS AND METHODS TO INACTIVATE AND/OR REDUCE PRODUCTION OF MICROBIAL TOXINS - The present invention is related to compositions and methods to treat, ameliorate and/or prevent morbidity and/or mortality from microbial infections. In particular, bacterial infections that are associated with the production and release of bacterial toxins. For example, many Clostridia bacteria, such as | 12-31-2015 |
20150376685 | Method for Bacterial Species Identification and Strain Typing - The present disclosure describes a method for identifying a strain or species of bacteria using a single locus sequence typing technique. The single locus useful in the method is the promoter region of the 16S rRNA operon. The method is useful to identify infectious bacteria in a subject, to identifying contaminants in a food source, as well as strain typing and genetic fingerprinting of bacterial families. | 12-31-2015 |
20160031832 | QUINAZOLINONE ANTIBIOTICS - A new class of antibiotics effective against methicillin-resistant | 02-04-2016 |
20160058843 | METHODS AND SYSTEM FOR INTERFERING WITH VIABILITY OF BACTERIA AND RELATED COMPOUNDS AND COMPOSITIONS - Provided herein are methods and systems for interfering with viability of bacteria and related compounds and compositions. | 03-03-2016 |
20160074480 | INNOVATIVE METHODS OF TREATMENTING TUBERCULOSIS - A Safe and effective treatment methods to cure and curtail tuberculosis affliction described using high dose Vitamin C, and other known anti- | 03-17-2016 |
20160075749 | ANTIMICROBIAL PEPTIDE - The disclosure relates to antimicrobial peptides, pharmaceutical compositions comprising the peptides and to uses thereof for treatment or prevention of microbial, bacterial, fungal, viral and parasitic infection. | 03-17-2016 |
20160081916 | Topical Composition and Carrier for Administration of Pharmaceutically or Cosmetically Active Ingredients - The present invention provides topical pharmaceutical or cosmetic compositions comprising a pharmaceutical or cosmetic carrier comprising at least 3% by weight of phospholipid; at least 20% by weight of C | 03-24-2016 |
20160095316 | COMPOSITIONS AND METHODS FOR THE REMOVAL OF BIOFILMS - Methods of breaking down a biofilm or inhibiting, preventing or treating a microbial infection that produces a biofilm are disclosed, which involves administration of a polypeptide that has one or more HMG-box domains to a subject suffering from the infection or having the biofilm. By competing with microbial proteins that bind to DNA scaffold in the biofilm, these polypeptides destabilize the biofilm leading to destruction and removal of the biofilm by the immune system. | 04-07-2016 |
20160115196 | SELF-ASSEMBLED MICRO-AND NANOSTRUCTURES - The present invention discloses self-assembled bioadhesive anti-microbial, anti-fouling and/or anti-oxidant micro- and nano-structures comprising a plurality of amino acids or peptides, wherein each amino acid is an aromatic amino acid comprising a catecholic moiety, and/or each peptide comprises at least one aromatic amino acid comprising a catecholic moiety. Further disclosed are methods and kits for preparing these micro- and nano-structures. Further disclosed are uses of these micro- and nano-structures in pharmaceutical, cosmetic and medical devices applications. | 04-28-2016 |
20160120936 | METHODS OF PREVENTING SURGICAL SITE INFECTIONS - Methods for preventing a tissue infection associated with the site of a tissue disruption, such as a surgical incision. The methods include contacting tissue at the site with a composition comprising ε-polylysine in a physiologically-acceptable carrier, such as an isotonic solution, powder or hemostatic material containing ε-polylysine. Also provided are kits for preparing antibacterial ε-polylysine compositions. | 05-05-2016 |
20160120946 | COMPOSITIONS COMPRISING GC-MACROPHAGE ACTIVATING FACTOR AND USES THEREOF - A pharmaceutical composition that includes stable Gc macrophage activating factor (GcMAF) or a biologically active variant or fragment thereof and at least one pharmaceutically acceptable excipient selected from the group consisting of a surfactant and a synthetic water-soluble polymer having surface activity. These compositions are storage stable and are used for treating a disease or disorder associated with macrophage activation. | 05-05-2016 |
20160130309 | MONOCINS AND METHODS OF USE - The disclosure relates to the identification, cloning, and expression of a genetic locus within a | 05-12-2016 |
20160145304 | CYSTOBACTAMIDES - The present invention provides cystobactamides of formula (I) and the use thereof for the treatment or prophylaxis of bacterial infections: | 05-26-2016 |
20160158315 | RECOMBINANT HUMAN CC10 AND COMPOSITIONS THEREOF FOR USE IN THE TREATMENT OF NASAL RHINITIS - The present invention relates generally to the use of recombinant human CC10 (rhCC10), also known as recombinant human uteroglobin, for use as a therapeutic in the treatment of nasal rhinitis, nasal sinusitis, chronic rhinosinusitis, and nasal polyposis. More particularly, the invention provides methods, including broadly the critical dosage ranges of rhCC10 and intranasal route of administration, which may be administered to safely and effectively treat the aforementioned conditions. The invention further provides a composition useful in administering rhCC10 to humans. | 06-09-2016 |
20160184220 | Method for the Prevention and Treatment of Acne - A system for treating and preventing multiple forms of acne includes applying a solution to the skin to assist maintaining the skin's natural acidic mantle of 4.0 to 6.5, preserve moisture transport properties, and maintain specialized lipid content, allowing the skin to function normally, and assisting the skin to heal wounds caused by acne and associated bacterial infections. The method steps include one or more of the following: applying the formulation with surfactants incorporated therein to the skin as a cleanser, rinsing with water; applying the solution, with or without surfactants, and allowing the solution to air dry; repeating the applications and allowing them to air dry throughout the day; and repeating the cleansing and rinsing steps and applying the solution and allowing to air dry before retiring. One or more of the method steps may be repeated on a continual basis, typically daily, for an extended period of time. | 06-30-2016 |
20160250283 | COMPOSITIONS AND METHODS FOR PROPHYLAXIS AND THERAPY OF CLOSTRIDIUM DIFFICILE INFECTION | 09-01-2016 |
20160376318 | POLYPEPTIDE, DNA MOLECULE ENCODING THE POLYPEPTIDE, VECTOR, PREPARATION METHOD AND USE - A polypeptide, a DNA molecule encoding the polypeptide, a vector, a preparation method and a use therefor are disclosed. The polypeptide comprises an amino acid sequence represented by formula (I) or formula (II): formula (I) comprises an amino acid sequence represented by SEQ ID NO: 1; formula (II) comprises an amino acid sequence obtained by subjecting the amino acid sequence represented by SEQ ID NO: 1 to modification, substituted, and deletion or addition of one or more amino acids. The polypeptide may be used in the preparation of drugs that treat or prevent diseases related to infections caused by bacteria, and can also be used in the preparation of drugs that promote tissue repair and wound healing. | 12-29-2016 |
20190144510 | MODIFIED ANTIMICROBIAL PEPTIDE DERIVED FROM AN ARGININE-RICH DOMAIN | 05-16-2019 |
20100331261 | USE OF ALPHA-1-ANTITRYPSIN FOR THE PREPARATION OF DRUGS FOR THE TREATMENT OF CHRONIC FATIGUE SYNDROME - The present invention relates to the use of alpha-1-antitrypsin for the preparation of effective drugs for the treatment of chronic fatigue syndrome. In addition, the present invention relates to the use of plasma or other therapeutic forms with an alpha-1-antitrypsin content sufficient to obtain a dose of 6 mg or more of alpha-1-antitrypsin per kg of body weight at a frequency of between 1 and 31 days. | 12-30-2010 |
20110251136 | GLUE COMPOSITION FOR LUNG VOLUME REDUCTION - The present invention relates to methods and compositions for sealing localized regions of damaged lung tissue to reduce overall lung volume. The glue compositions provide a glue featuring an adhering moiety coupled to one or more other moieties including, for example, a cross-linkable moiety and/or one other adhering moiety. The methods and compositions of the invention find use, for example, in treating pulmonary conditions, such as emphysema. | 10-13-2011 |
20130252906 | COMPOUNDS AND METHODS FOR TREATING OR PREVENTING DISEASE CONDITIONS ASSOCIATED WITH ALPHA-1-ANTITRYPSIN - Pharmacological chaperone compounds and methods for the treatment of an individual having, or at risk of having, a disease condition associated with alpha-1-antitrypsin by using said compounds are disclosed. In particular, such methods are useful for the treatment or prevention of lung disorders associated with alpha-1-antitrypsin deficiency as well as liver disorders associated with an excess of alpha-1-antitrypsin. Suitable pharmacological chaperones include peptides and low-molecular weight compounds. Also provided is an assay for determining whether a test compound modulates alpha-1-antitrypsin activity. | 09-26-2013 |
20130310325 | ADMINISTRATION OF SERINE PROTEASE INHIBITORS TO THE STOMACH - The inventors have unexpectedly discovered that shock and/or potential multi-organ failure due to shock can be effectively treated by administration of liquid high-dose protease inhibitor formulations to a location upstream of where pancreatic proteases are introduced into the gastrointestinal tract. Most preferably, administration is directly to the stomach, for example, via nasogastric tube under a protocol effective to treat shock by such administration without the need of providing significant quantities of the protease inhibitor to the jejunum and/or ileum. | 11-21-2013 |
20140073588 | GLUE COMPOSITION FOR LUNG VOLUME REDUCTION - The present invention relates to methods and compositions for sealing localized regions of damaged lung tissue to reduce overall lung volume. The glue compositions provide a glue featuring an adhering moiety coupled to one or more other moieties including, for example, a cross-linkable moiety and/or one other adhering moiety. The methods and compositions of the invention find use, for example, in treating pulmonary conditions, such as emphysema. | 03-13-2014 |
20140213531 | TEMPLATE-FIXED BETA-HAIRPIN PEPTIDOMIMETICS WITH PROTEASE INHIBITORY ACTIVITIY - Template-fixed β-hairpin peptidomimetics of the general formulae | 07-31-2014 |
20140371160 | NOVEL ALPHA-1 ANTITRYPSIN VARIANT, PREPARATION METHOD THEREOF AND USE THEREOF - A novel alpha-1 antitrypsin variant, a method of preparing the same, and use thereof are provided. The alpha-1 antitrypsin variant has excellent stability in the body and maintains an inhibitory effect on elastase activities because the blood half-life (t | 12-18-2014 |
20150011479 | Alpha1 proteinase inhibitor peptides methods and use - The invention is directed to the use of peptides that can bind and block the interaction of α1 proteinase inhibitor (α | 01-08-2015 |
20150025019 | Method for Dosage Adjustment of Drugs that Prevent Elastic Fiber Breakdown - Elastic fiber damage is responsible for the distention and rupture of alveolar walls in chronic obstructive pulmonary disease (COPD). The current invention comprises a method of adjusting the a dosage of a drug that prevents such elastic fiber damage by employing a feedback loop consisting of measuring the levels of the unique elastic fiber breakdown products, desmosine and isodesmosine in body fluids, preferably sputum. The recent discovery that sputum levels of desmosine and isodesmosine are responsive to treatment with aerosolized hyaluronan in COPD patients makes dosage adjustment both feasible and desirable. This process of dosage adjustment may be applicable to any drug that prevents lung elastic fiber damage, such as alpha-1-antitrypsin, other anti-elastase agents, and antioxidants. It is anticipated that such dosage adjustment will become the “standard of care” in the treatment of COPD patients. | 01-22-2015 |
20150320846 | METHODS OF TREATMENT USING ALPHA-1-ANTITRYPSIN COMPOSITIONS - A streamlined method for purifying alpha-1-antitrypsin (AAT) from an AAT-containing protein mixture, such as Coh fraction IV precipitate, is provided. In the method of the invention, contaminating proteins are destabilized by cleavage of disulfide bonds with a reducing reagent, such as dithiol, which does not affect AAT. The destabilized proteins are then preferentially adsorbed on a solid protein-adsorbing material, without the addition of a salt as a precipitante. Separation of the solid absorbent from the solution leaves a purified AAT solution that is directly suitable for chromatographic purification, without the need for extensive desalting as in prior art processes. A process incorporating this method, which provides pharmaceutical grade AAT in high yield on a commercial scale, is also described. | 11-12-2015 |
20160011207 | DIAGNOSIS AND THERAPY OF CHRONIC INFLAMMATION-INDUCED DISORDERS | 01-14-2016 |
20160103138 | METHODS FOR ANALYZING ELASTIC FIBER INJURY MARKERS AND DIAGNOSIS OF DISEASES ASSOCIATED WITH ELASTIC FIBER INJURY - The present invention provides, inter alia, methods for measuring the amount of a marker of elastic fiber injury in a sample. The methods include contacting a sample with a compound of formula (1) and carrying out mass spectrometry on the sample containing the compound of formula (1). Also provided are methods of diagnosing whether a subject has a disease characterized by elastic fiber injury, a method for improving the accuracy and precision of mass spectroscopy analysis of a marker of elastic fiber injury, and kits for determining, by mass spectrometry, the amount of a marker of elastic fiber injury in a sample from a subject. Further provided are methods for preventing the progression of the effects associated with alpha-1 antitrypsin deficiency (AATD) in a subject with normal lung function. | 04-14-2016 |